BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asher WB, Terry DS, Gregorio GGA, Kahsai AW, Borgia A, Xie B, Modak A, Zhu Y, Jang W, Govindaraju A, Huang LY, Inoue A, Lambert NA, Gurevich VV, Shi L, Lefkowitz RJ, Blanchard SC, Javitch JA. GPCR-mediated β-arrestin activation deconvoluted with single-molecule precision. Cell 2022;185:1661-1675.e16. [PMID: 35483373 DOI: 10.1016/j.cell.2022.03.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Manning JJ, Rawcliffe G, Finlay DB, Glass M. Cannabinoid 1 (CB(1) ) receptor arrestin subtype-selectivity and phosphorylation dependence. Br J Pharmacol 2023;180:369-82. [PMID: 36250246 DOI: 10.1111/bph.15973] [Reference Citation Analysis]
2 Xie B, Le Rouzic VP, Goldberg A, Tsai MM, Chen L, Zhang T, Sinha A, Pan YX, Baumann MH, Shi L. Binding preference at the μ-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl. Neuropharmacology 2023;227:109442. [PMID: 36731721 DOI: 10.1016/j.neuropharm.2023.109442] [Reference Citation Analysis]
3 Dawed AY, Mari A, Brown A, McDonald TJ, Li L, Wang S, Hong MG, Sharma S, Robertson NR, Mahajan A, Wang X, Walker M, Gough S, Hart LM', Zhou K, Forgie I, Ruetten H, Pavo I, Bhatnagar P, Jones AG, Pearson ER; DIRECT consortium. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol 2023;11:33-41. [PMID: 36528349 DOI: 10.1016/S2213-8587(22)00340-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Salas-Estrada L, Fiorillo B, Filizola M. Metadynamics simulations leveraged by statistical analyses and artificial intelligence-based tools to inform the discovery of G protein-coupled receptor ligands. Front Endocrinol (Lausanne) 2022;13:1099715. [PMID: 36619585 DOI: 10.3389/fendo.2022.1099715] [Reference Citation Analysis]
5 Bumbak F, Inoue A, Pons M, Paniagua JC, Yan F, Wu H, Robson SA, Bathgate RAD, Scott DJ, Gooley PR, Ziarek JJ. The dynamic nature of neurotensin receptor 1 (NTS1) allostery and signaling bias.. [DOI: 10.1101/2022.11.25.517797] [Reference Citation Analysis]
6 Janetzko J, Kise R, Barsi-Rhyne B, Siepe DH, Heydenreich FM, Kawakami K, Masureel M, Maeda S, Garcia KC, von Zastrow M, Inoue A, Kobilka BK. Membrane phosphoinositides regulate GPCR-β-arrestin complex assembly and dynamics. Cell 2022;185:4560-4573.e19. [PMID: 36368322 DOI: 10.1016/j.cell.2022.10.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Maharana J, Sarma P, Yadav MK, Saha S, Singh V, Saha S, Chami M, Banerjee R, Shukla AK. Structural snapshots uncover a lock-and-key type conserved activation mechanism of β-arrestins by GPCRs.. [DOI: 10.1101/2022.10.10.511556] [Reference Citation Analysis]
8 Xu Z, Shao Z. Dynamic mechanism of GPCR-mediated β-arrestin: a potential therapeutic agent discovery of biased drug. Signal Transduct Target Ther 2022;7:283. [PMID: 35961979 DOI: 10.1038/s41392-022-01140-6] [Reference Citation Analysis]
9 Barsi-rhyne B, Manglik A, von Zastrow M. Discrete GPCR-triggered endocytic modes enable β-arrestins to flexibly regulate cell signaling.. [DOI: 10.1101/2022.07.13.499995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Foley JF. A twist in β-arrestin's tail. Sci Signal 2022;15:eadd1034. [PMID: 35609126 DOI: 10.1126/scisignal.add1034] [Reference Citation Analysis]